The world leader in CTPS1 inhibition for the targeted treatment of cancer.
Home
Dencatistat, a novel drug with the potential to yield a highly selective, safe and effective cancer treatment for both blood cancers and solid tumours.
Our lead asset, dencatistat (STP938), is a first-in-class, highly selective, orally bioavailable, targeted oncology therapy that aims to become a key drug for a multitude of cancer treatment regimens.
Watch this short video to find out more about our lead CTPS1 selective inhibitor, dencatistat, and our breakthrough science.
Current Blood Cancer Treatment
3
Every 3 minutes someone is diagnosed with leukemia, lymphoma or myeloma in the US
100
There are over a hundred different types of blood cancer
0
No improvement in 5-year survival rates for peripheral T cell lymphoma patients in the past 20 years
Current Solid Tumour Treatment
2.5
2.5 million people diagnosed with advanced cancer every year in Europe and the US
1-2
Average survival for those diagnosed with advanced cancer is 1-2 years
20
Up to 20% of all cancers have lost CTPS2 expression and may benefit from selective CTPS1 inhibition
Watch the leadership team discuss our lead CTPS1 inhibitor STP938
Dencatistat (STP938) is entering clinical trials for the treatment of blood cancers with the potential for accelerated approval from a single arm Phase II study.
Dencatistat (STP938)
Our lead CTPS1 inhibitor dencatistat has the potential to become a key treatment for a multitude of cancers. Dencatistat is in clinical development for the treatment of blood cancers, with the potential for accelerated approval from a single arm phase 2 study.
Dencatistat is also in clinical development for solid tumours with the initial focus on ovarian cancer. In the future dencatistat could also form the backbone of various treatment regimens for solid tumours.
Step Pharma
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex
01630 Saint-Genis-Pouilly
France
